The response rates of HNSCC to checkpoint blockade are below 20%, to increase its efficacy Tan et al., engineered a tumor antigen-targeted nanosatellite vehicle to enhance the efficacy of STING (stimulator of interferon genes) agonist and sensitize SOX2-expressing HNSCC to checkpoint blockade (148). Here, STING1 is linked to head and neck squamous cell carcinoma.